References

  1. Ramappa V, Aithal GP. Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management. Journal of clinical and experimental hepatology. 2013 Mar;3(1):37-49. PubMed | Google Scholar

  2. World Health Organization. Global tuberculosis report 2014. Geneva: World Health Organization, 2014. Google Scholar

  3. World Health Organization. Moroccan tuberculosis report 2014. Geneva: World Health Organization, 2014. Google Scholar

  4. Isa SE, Ebonyi AO, Shehu NY, Idoko P, Anejo-Okopi JA, Simji G, Odesanya RU, Abah IO, Jimoh HO. Antituberculosis drugs and hepatotoxicity among hospitalized patients in jos, Nigeria. International journal of mycobacteriology. 2016 Mar;5(1):21-6. PubMed | Google Scholar

  5. Shakya R, Subba Rao B, Shrestha B. Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors. The annals of pharmacotherapy. 2004 Jun;38(6):1074-9. PubMed | Google Scholar

  6. Huiri A, Xueqiong W, Zhongyuan W, Jing X, Shaohua Z, Kun Wang. The clinical characteristics of anti-tuberculosis drug induced liver injury in 2457 hospitalized patients with tuberculosis in China. African journal of pharmacy and pharmacology. 2013;7(13):710-714. PubMed | Google Scholar

  7. Tostmann A, Boeree MJ, Aarnoutse RE, et al. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J gastroenterol hepatol. 2008 Feb;23(2):192-202. PubMed | Google Scholar

  8. Aouam K, Chaabane A, Loussaief C, Ben Romdhane F, Boughattas NA, Chakroun M. Adverse effects of antitubercular drugs: epidemiology, mechanisms, and patient management. Med Mal Infect. 2007; 37(5):253-61. PubMed | Google Scholar

  9. Jeong I, Park JS, Co YJ, Yoon H, Song J, Lee CT and Lee JH. Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels. J Korean Med Sci. 2015 Feb; 30(2): 167–172. PubMed | Google Scholar

  10. Anand AC, Seth AK, Paul M, Puri P. Risk factors of hepatotoxicity during anti-tuberculosis treatment. MJAFI. 2006 Jan; 62(1):45-49. PubMed | Google Scholar

  11. Abera W, Cheneke W, Abebe G. Incidence of antituberculosis-drug-induced heptotoxicity and associated risk factors among tuberculosis patients in Dawro zone, South Ethiopia: A cohort study. Int J of mycobacteriology. 2016 Mar;5(1):14-20 Epub 2015 Oct 30. PubMed | Google Scholar

  12. Mahmood K, Hussain A, Lal Jairamani K, Talib A, Abbasi BU, Salkeen S. Hepatotoxicity with antituberculosis drugs: The risk factors. Pakistan journal of medical sciences. 2007;23:33-38. PubMed | Google Scholar

  13. Xiang Y, Ma L, Wu W et al. The incidence of liver injury in uyghur patients treated for TB in xinjiang uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1. PloS one. 2014;9:e85905. PubMed | Google Scholar

  14. Pande JN, Singh SPN, Khilnani GC, Khilnani S, Tandon RK. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax Journal. 1996 Feb;51(2):132-6. PubMed | Google Scholar

  15. Tost JR, Vidal R, Diaz-Cabanela D, Jimenez A, Broquetas JM. Severe hepatotoxicity due to antituberculosis drugs in spain. Int j tuberc lung dis. 2005 May;9(5):534-40. PubMed | Google Scholar

  16. Yee D, Valiquette C, PelletierM, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis.Am J Respir Crit Care Med. 2003 Jun 1;167(11):1472-7. Epub 2003 Jan 31. PubMed | Google Scholar

  17. Van Hest R, Baars H, Kik S et al. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment. Clin Infect Dis. 2004 Aug 15;39(4):488-96. Epub 2004 Jul 30. PubMed | Google Scholar

  18. Sharifzadeh M, Rasoulinejad M, Valipour F, Nouraie M, Vaziri S. Evaluation of patient-related factors associated with causality, preventability, predictability and severity of hepatotoxicity during antituberculosis treatment. Pharmacol Res. 2005 Apr;51(4):353-8. PubMed | Google Scholar

  19. Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am j Respir.Crit Care Med. 2002 Oct 1;166(7):916-9. PubMed | Google Scholar

  20. Guaoua S, Ratbi I, Laarbi FZ, Elalaoui Chafai S, Cherkaoui Jaouad I, Barkat A, Sefiani A. Distribution of allelic and genotypic frequencies of NAT2 and CYP2E1 variants in Moroccan population. BMC Genetics. 2014 Dec 29;15:156. PubMed | Google Scholar